New strategy aims to boost use of injectable HIV prevention

NCT ID NCT07649551

Not yet recruiting Knowledge-focused Sponsor: University of Minnesota Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a method to help clinics prescribe long-acting injectable PrEP, a shot that prevents HIV. Researchers will work with 20 healthcare providers and staff to improve how they offer this option. The goal is to see if a simple, flexible strategy can increase the number of eligible patients who get the injection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Plan-Do-Study-Act implementation strategy
What this could lead to: If successful, this could improve how clinics offer long-acting injectable PrEP, making HIV prevention more accessible.
What could go wrong: This is a small, early-stage study with only 20 participants, so results may not apply broadly. It focuses on provider behavior, not patient outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS

More trials for these conditions

Other studies related to the condition(s) this trial covers.